AI-Driven Platform Innovation

  • Our high-throughput approach is fast and cost effective.
  • Does not depend on knowledge or assumption of the target protein.
  • Simultaneous discovery of multiple biologically relevant targets and antibodies.
  • Enables the selection of functionally relevant B cells.
  • Maximize the discover of antibodies with potent antitumor activity.
  • Rapid ability to translate the findings into a clinically relevant therapy.